Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V. Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M. N. Behrens, Alexandra Dopfer-Jablonka
{"title":"接种 mRNA Omicron JN.1 疫苗后的体液免疫","authors":"Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V. Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M. N. Behrens, Alexandra Dopfer-Jablonka","doi":"10.1101/2024.09.04.24313057","DOIUrl":null,"url":null,"abstract":"In late June 2024, the European Medicines Agency (EMA) recommended market authorization for a monovalent COVID-19 mRNA-vaccine based on JN.1 spike. We assessed immune responses in n=42 health-care workers (median age 47 years, interquartile range, IQR 19·5 years, 48% male), who in August 2024 were vaccinated with 30 μg of the updated mRNA omicron JN.1 vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany). Humoral immune responses were analyzed directly prior to and 13 days after vaccination.","PeriodicalId":501509,"journal":{"name":"medRxiv - Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Humoral Immunity after mRNA Omicron JN.1 Vaccination\",\"authors\":\"Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V. Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M. N. Behrens, Alexandra Dopfer-Jablonka\",\"doi\":\"10.1101/2024.09.04.24313057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In late June 2024, the European Medicines Agency (EMA) recommended market authorization for a monovalent COVID-19 mRNA-vaccine based on JN.1 spike. We assessed immune responses in n=42 health-care workers (median age 47 years, interquartile range, IQR 19·5 years, 48% male), who in August 2024 were vaccinated with 30 μg of the updated mRNA omicron JN.1 vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany). Humoral immune responses were analyzed directly prior to and 13 days after vaccination.\",\"PeriodicalId\":501509,\"journal\":{\"name\":\"medRxiv - Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.04.24313057\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.04.24313057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Humoral Immunity after mRNA Omicron JN.1 Vaccination
In late June 2024, the European Medicines Agency (EMA) recommended market authorization for a monovalent COVID-19 mRNA-vaccine based on JN.1 spike. We assessed immune responses in n=42 health-care workers (median age 47 years, interquartile range, IQR 19·5 years, 48% male), who in August 2024 were vaccinated with 30 μg of the updated mRNA omicron JN.1 vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany). Humoral immune responses were analyzed directly prior to and 13 days after vaccination.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
